Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Reducing mitochondrial reads in ATAC-seq using CRISPR/Cas9

Open access
Montefiori, Lindsey, Hernandez, Liana, Zhang, Zijie, Gilad, Yoav, Ober, Carole, Crawford, Gregory, Nobrega, Marcelo, Jo Sakabe, Noboru · 2017 · Scientific Reports

Published version of a preprint

Abstract

ATAC-seq is a high-throughput sequencing technique that identifies open chromatin. Depending on the cell type, ATAC-seq samples may contain ~20–80% of mitochondrial sequencing reads. As the regions of open chromatin of interest are usually located in the nuclear genome, mitochondrial reads are typically discarded from the analysis. We tested two approaches to decrease wasted sequencing in ATAC-seq libraries generated from lymphoblastoid cell lines: targeted cleavage of mitochondrial DNA fragments using CRISPR technology and removal of detergent from the cell lysis buffer. We analyzed the effects of these treatments on the number of usable (unique, non-mitochondrial) reads and the number and quality of peaks called, including peaks identified in enhancers and transcription start sites. Both treatments resulted in considerable reduction of mitochondrial reads (1.7 and 3-fold, respectively). The removal of detergent, however, resulted in increased background and fewer peaks. The highest number of peaks and highest quality data was obtained by preparing samples with the original ATAC-seq protocol (using detergent) and treating them with CRISPR. This strategy reduced the amount of sequencing required to call a high number of peaks, which could lead to cost reduction when performing ATAC-seq on large numbers of samples and in cell types that contain a large amount of mitochondria.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-017-02547-w

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 ATAC-seq read densities in the mitochondrial chromosome and one nuclear genome region. Top: The mitochondrial chromosome (chrM) is densely covered by uniquely mapped reads. Genomic location of the 100 mitochondrial guide RNAs (red tick marks) designed to target the human mitochondrial chromosome (top). Bottom: compare chrM to a 16.5 kb region of the nuclear genome (hg38, chr9:90,791,567–90,808,137). The chrM and chr9 tracks are shown in different height scales for easier visualization. Seven samples were pooled and 227 M reads were sampled.
Figure 1 ATAC-seq read densities in the mitochondrial chromosome and one nuclear genome region. Top: The mitochondrial chromosome (chrM) is densely covered by uniquely mapped reads. Genomic location of the 100 mitochondrial guide RNAs (red tick marks) designed to target the human mitochondrial chromosome (top). Bottom: compare chrM to a 16.5 kb region of the nuclear genome (hg38, chr9:90,791,567–90,808,137). The chrM and chr9 tracks are shown in different height scales for easier visualization. Seven samples were pooled and 227 M reads were sampled.CC BY · PubMed Central
Figure 2 ATAC-seq was performed on human lymphoblastoid cells and half of each sample was left untreated (green) and the other half was treated with anti-mt CRISPR (purple). (a) Representative genomic region (hg38, chr2:74,425,417–74,586,546) showing read counts (usable reads) in 5 replicate pairs (DT) at the same sequencing depth of 21.9 M reads. Differences between treated and untreated samples were minimal, indicating that the treatment did not damage the samples. (b) ATAC-seq reads in the mitochondrial chromosome and in a 16.5 kb region of chromosome 9 around the SYF promoter (same as Fig. 1). For each condition, all samples were pooled together and 227 M reads were sampled. (c) Treated samples yielded 1.7-fold fewer mitochondrial reads compared to untreated samples. (d) Accordingly, the number of unique, non-mitochondrial (usable) reads was 1.7-fold higher in treated samples than in their untreated counterparts. (e) At the same sequencing depth, 1.6-fold more peaks were called in the treated samples. Only 6 data points are shown because the treated halves of samples 18 and 19 (same batch) had only 14.5 M and 9.8 M reads each and were combined for improved peak calling. (f) Anti-mt CRISPR-treated samples shared a similar number of peaks with treated replicates and untreated samples. The top 20,000 peaks of each sample were used in this analysis. Comparison of peaks at the read count level also supports that peaks from treated samples do not substantially differ from untreated samples. Fold-differences were calculated on the medians. (c–e): all samples normalized to 21.9 M sequenced reads.
Figure 2 ATAC-seq was performed on human lymphoblastoid cells and half of each sample was left untreated (green) and the other half was treated with anti-mt CRISPR (purple). (a) Representative genomic region (hg38, chr2:74,425,417–74,586,546) showing read counts (usable reads) in 5 replicate pairs (DT) at the same sequencing depth of 21.9 M reads. Differences between treated and untreated samples were minimal, indicating that the treatment did not damage the samples. (b) ATAC-seq reads in the mitochondrial chromosome and in a 16.5 kb region of chromosome 9 around the SYF promoter (same as Fig. 1). For each condition, all samples were pooled together and 227 M reads were sampled. (c) Treated samples yielded 1.7-fold fewer mitochondrial reads compared to untreated samples. (d) Accordingly, the number of unique, non-mitochondrial (usable) reads was 1.7-fold higher in treated samples than in their untreated counterparts. (e) At the same sequencing depth, 1.6-fold more peaks were called in the treated samples. Only 6 data points are shown because the treated halves of samples 18 and 19 (same batch) had only 14.5 M and 9.8 M reads each and were combined for improved peak calling. (f) Anti-mt CRISPR-treated samples shared a similar number of peaks with treated replicates and untreated samples. The top 20,000 peaks of each sample were used in this analysis. Comparison of peaks at the read count level also supports that peaks from treated samples do not substantially differ from untreated samples. Fold-differences were calculated on the medians. (c–e): all samples normalized to 21.9 M sequenced reads.CC BY · PubMed Central
Figure 3 Effect of detergent removal from the ATAC-seq protocol. (a) The fraction of mitochondrial reads in samples prepared without detergent was considerably smaller than those prepared with the original protocol. Treatment with anti-mt DNA CRISPR led to further decrease of mitochondrial reads (3.1-fold). (b) The fraction of unique, non-mitochondrial reads was considerably higher when detergent was not used. Surprisingly, the anti-mt DNA CRISPR treatment had only a marginal effect on the fraction of usable reads (1.1-fold increase). (c) At the same sequencing depth, only 1.1-fold more peaks were called in the ND treated samples. DT samples 18 and 19 were combined as in Fig. 2c. (d) ND samples displayed higher background (the number of non-mitochondrial reads outside peaks identified in any DT or ND sample). Numbers in blue above the bars are the ratio between number of reads in peaks and the number of background reads (signal/noise) (e) An example illustrating the higher background in ND samples, highlighted by the dashed boxes (chr6:420,146–448,555). Fold-differences calculated on medians.
Figure 3 Effect of detergent removal from the ATAC-seq protocol. (a) The fraction of mitochondrial reads in samples prepared without detergent was considerably smaller than those prepared with the original protocol. Treatment with anti-mt DNA CRISPR led to further decrease of mitochondrial reads (3.1-fold). (b) The fraction of unique, non-mitochondrial reads was considerably higher when detergent was not used. Surprisingly, the anti-mt DNA CRISPR treatment had only a marginal effect on the fraction of usable reads (1.1-fold increase). (c) At the same sequencing depth, only 1.1-fold more peaks were called in the ND treated samples. DT samples 18 and 19 were combined as in Fig. 2c. (d) ND samples displayed higher background (the number of non-mitochondrial reads outside peaks identified in any DT or ND sample). Numbers in blue above the bars are the ratio between number of reads in peaks and the number of background reads (signal/noise) (e) An example illustrating the higher background in ND samples, highlighted by the dashed boxes (chr6:420,146–448,555). Fold-differences calculated on medians.CC BY · PubMed Central
Figure 4 Comparison of the fraction of functional regions overlapping ATAC-seq peaks. (a) The fraction of transcription start sites (TSS’s) overlapping an ATAC-seq peak (+/− 1 kb) was slightly higher in the DT samples than in the ND samples (1.05-fold). (b) Treated DT samples identified a greater number of Epigenome Roadmap GM12878 lymphoblastoid cell active enhancers (1.9-fold) than anti-mt CRISPR untreated ND samples. Fold-differences calculated on medians.
Figure 4 Comparison of the fraction of functional regions overlapping ATAC-seq peaks. (a) The fraction of transcription start sites (TSS’s) overlapping an ATAC-seq peak (+/− 1 kb) was slightly higher in the DT samples than in the ND samples (1.05-fold). (b) Treated DT samples identified a greater number of Epigenome Roadmap GM12878 lymphoblastoid cell active enhancers (1.9-fold) than anti-mt CRISPR untreated ND samples. Fold-differences calculated on medians.CC BY · PubMed Central
Figure 5 Comparison of ATAC-seq samples normalized by total number of usable reads instead of total number of sequenced reads. (a) The number of peaks is higher in DT than in ND samples. (b) The fraction of TSS and (c) enhancers identified by ATAC-seq peaks is higher in DT than in ND samples. (d) DT samples have more reads in peaks than ND samples. The differences between samples treated with anti-mt CRISPR and left untreated are not statistically significant, showing that the anti-mt CRISPR treatment does not damage the samples.
Figure 5 Comparison of ATAC-seq samples normalized by total number of usable reads instead of total number of sequenced reads. (a) The number of peaks is higher in DT than in ND samples. (b) The fraction of TSS and (c) enhancers identified by ATAC-seq peaks is higher in DT than in ND samples. (d) DT samples have more reads in peaks than ND samples. The differences between samples treated with anti-mt CRISPR and left untreated are not statistically significant, showing that the anti-mt CRISPR treatment does not damage the samples.CC BY · PubMed Central
Figure 6 Modifications of the anti-mt CRISPR treatment. Compared to the treatment shown in Fig. 1 (100X gRNA, 100X Cas9, 1 h incubation), labeled “standard”, modifications in the treatment did not show improvement. The number of peaks is comparable or even lower in the modified treatments, compared to the standard treatment. Due to the low number of reads in 6 samples, the results presented were obtained with 9.8 M reads randomly sampled. See also Supplemental Fig. S3.
Figure 6 Modifications of the anti-mt CRISPR treatment. Compared to the treatment shown in Fig. 1 (100X gRNA, 100X Cas9, 1 h incubation), labeled “standard”, modifications in the treatment did not show improvement. The number of peaks is comparable or even lower in the modified treatments, compared to the standard treatment. Due to the low number of reads in 6 samples, the results presented were obtained with 9.8 M reads randomly sampled. See also Supplemental Fig. S3.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 54

Metadata

Authors
Montefiori, L., Hernandez, L., Zhang, Z., Gilad, Y., Ober, C., Crawford, G., Nobrega, M., & Jo Sakabe, N.
Affiliations
  • University of Chicago (US)
  • Duke University (US)
Venue
Scientific Reports
Published
2017-05-26
Volume
7
Issue
1
Pages
2451-2451
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2949074346
Cited by
54
References
15
Citations by year
2026: 2 · 2025: 1 · 2024: 3 · 2023: 7 · 2022: 4 · 2021: 5 · 2020: 10 · 2019: 14 · 2018: 8
FWCI
3.57
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • March of Dimes Foundation
  • Northwestern University
  • University of Chicago
  • National Institutes of Health
  • National Institute of General Medical Sciences (GM007197, T32GM007197)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK020595)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
Keywords
ATAC-seq, mitochondrial reads, CRISPR/Cas9, open chromatin, enhancers, transcription start sites, detergent removal, cell lysis buffer, sequencing cost reduction, lymphoblastoid cell lines, peak calling
MeSH terms
Cell Line, Cell Nucleus, DNA, Mitochondrial, Humans, Lymphocytes, Mitochondria, High-Throughput Nucleotide Sequencing, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reducing mitochondrial reads in ATAC-seq using CRISPR/Cas9. https://app.cochat.ai/papers/10.1038/s41598-017-02547-w
The paper
Montefiori, L., Hernandez, L., Zhang, Z., Gilad, Y., Ober, C., Crawford, G., Nobrega, M., & Jo Sakabe, N. (2017). Reducing mitochondrial reads in ATAC-seq using CRISPR/Cas9. Scientific Reports. https://doi.org/10.1038/s41598-017-02547-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.